ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0332

Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial

Jeffrey R Curtis1, Iain McInnes2, Proton Rahman3, William Tillett4, Philip Mease5, Alexa Kollmeier6, Elizabeth Hsia7, Bei Zhou8, Prasheen Agarwal8, Steven Peterson9 and Chenglong Han8, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 4Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, 5Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 6Janssen Research & Development, LLC, La Jolla, CA, 7Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, 8Janssen Research & Development, LLC, Spring House, PA, 9Janssen Immunology Global Commercial Strategy Organization, Horsham, PA

Meeting: ACR Convergence 2020

Keywords: ,

Session Information

Date: Friday, November 6, 2020

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific MAb Guselkumab (GUS) in PsA patients, who experience impaired physical function, resulting in disability, work productivity loss, and economic consequences.1 This study aimed to evaluate the effect of GUS on impaired work productivity and daily activity in DISC 2 using the Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI-PsA).

Methods: Bio-naïve adults with active PsA despite nonbiologic DMARDs &/or NSAIDs received subcutaneous GUS 100 mg every (q) 4 weeks (W); GUS 100 mg Week 0, Week 4, q8W; or placebo (PBO). WPAI-PsA assesses, due to PsA over the previous week, work time missed (absenteeism), impairment while working (presenteeism), and impaired overall work productivity (absenteeism + presenteeism) and daily activity. Percentage change from baseline was analyzed for WPAI-PsA domains using mixed-effect model repeated measure (MMRM). Indirect savings from improved overall work productivity were estimated with 2018 US mean yearly wage estimate (all occupations).2

Results: At Week 24, impaired overall work productivity and daily activity were improved 20-22% in GUS-treated and 10-11% in PBO-treated patients (Table). Potential yearly indirect savings from improved overall work productivity was $10,242 with GUS q8W and $10,404 with GUS q4W vs $5,648 with PBO; $4,594 and $4,756 difference, respectively.

Conclusion: Improvement in overall work productivity and daily activity was greater with GUS versus PBO among patients with moderate-to-severe PsA, resulting in potential annual incremental economic gains.

References:

  1. Tillett W et al. Rheumatol (Oxford). 2012; 51:275–283.
  2. US Bureau of Labor Statistics. May 2018 National Occupational Employment and Wage Estimates United States. https://www.bls.gov/oes/current/oes_nat.htm#00-000

Table. Model-based estimates of mean change from baseline in WPAI-PsA domains. Data are % (95% CI). *p>0.05, †p < 0.05, ‡p < 0.001. LSmean, p values based on MMRM. LSmean diffs, p values vs PBO. GUS, Guselkumab; LSMean, least squares mean; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; WPAI-PsA, work productivity and activity impairment questionnaire: psoriatic arthritis.

Disclosure: J. Curtis, AbbVie, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb, 2, 5, Corrona, 2, 5, Janssen, 2, 5, Lilly, 2, 5, Myriad, 2, 5, Pfizer, 2, 5, Regeneron, 2, 5, Roche, 2, 5, UCB, 2, 5, Gilead Sciences, Inc., 5, Sanofi, 5; I. McInnes, Novartis, 9, AbbVie, 9, Celgene, 9, Janssen, 2, 9, UCB, 2, 9, Bristol Myers Squibb, 2, 9, AstraZeneca, 2, Boehringer Ingelheim, 2, Lilly, 9, LEO, 9; P. Rahman, AbbVie, 5, 8, Amgen, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Janssen, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Abbott, 8, Centacor, 8, Merck, 8, Bristol Myers Squibb, 5, 8, Roche, 5; W. Tillett, Abbvie, 5, 8, Amgen Inc., 5, 8, Celgene, 5, 8, Eli Lilly and Company, 5, 8, Janssen, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, UCB Pharma, 5, 8; P. Mease, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Sun, 2, 5, UCB, 2, 5, 8, AbbVie, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, GlaxoSmithKline, 5; A. Kollmeier, Janssen Research & Development, LLC, 3, Johnson & Johnson, 1; E. Hsia, Janssen Research & Development, LLC, 3, Johnson & Johnson, 1; B. Zhou, Janssen Reserach & Development, LLC, 3, Johnson & Johnson, 1; P. Agarwal, Janssen Research & Development, LLC, 3, Johnson & Johnson, 1; S. Peterson, Janssen Research & Development, LLC, 3; C. Han, Janssen Research & Development, LLC, 3.

To cite this abstract in AMA style:

Curtis J, McInnes I, Rahman P, Tillett W, Mease P, Kollmeier A, Hsia E, Zhou B, Agarwal P, Peterson S, Han C. Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/guselkumab-improved-work-productivity-and-daily-activity-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-trial/. Accessed January 28, 2022.

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/guselkumab-improved-work-productivity-and-daily-activity-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-trial/